136 related articles for article (PubMed ID: 37506342)
21. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
[TBL] [Abstract][Full Text] [Related]
22. CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2.
Laotee S; Duangkaew M; Jivapetthai A; Tharakhet K; Kaewpang P; Prompetchara E; Phumiamorn S; Sapsutthipas S; Trisiriwanich S; Somsaard T; Roytrakul S; Duangkhae P; Ongpipattanakul B; Limpikirati P; Pornputtapong N; Arunmanee W
PLoS One; 2023; 18(7):e0288486. PubMed ID: 37450510
[TBL] [Abstract][Full Text] [Related]
23. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
25. Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccination.
Liang B; Xiang T; Wang H; Li Z; Quan X; Feng X; Li S; Lu S; Fan L; Xu L; Wang T; Wang X; Zhu B; Wang J; Yang D; Liu J; Zheng X
Front Immunol; 2022; 13():966098. PubMed ID: 35979361
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.
Wang Y; Wang L; Cao H; Liu C
J Med Virol; 2021 Feb; 93(2):892-898. PubMed ID: 32691875
[TBL] [Abstract][Full Text] [Related]
27. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.
Baz M; Samant M; Zekki H; Tribout-Jover P; Plante M; Lanteigne AM; Hamelin ME; Mallett C; Papadopoulou B; Boivin G
Clin Vaccine Immunol; 2012 Feb; 19(2):209-18. PubMed ID: 22190392
[TBL] [Abstract][Full Text] [Related]
28. Comparative evaluation of two hemagglutinating encephalomyelitis coronavirus vaccine candidates in mice.
Chen K; Zhao K; He W; Gao W; Zhao C; Wang L; Pan W; Song D; Wang C; Gao F
Clin Vaccine Immunol; 2012 Jul; 19(7):1102-9. PubMed ID: 22518008
[TBL] [Abstract][Full Text] [Related]
29. TLR9 and STING agonists cooperatively boost the immune response to SARS-CoV-2 RBD vaccine through an increased germinal center B cell response and reshaped T helper responses.
Yang JX; Tseng JC; Tien CF; Lee CY; Liu YL; Lin JJ; Tsai PJ; Liao HC; Liu SJ; Su YW; Hsu LC; Chen JK; Huang MH; Yu GY; Chuang TH
Int J Biol Sci; 2023; 19(9):2897-2913. PubMed ID: 37324951
[TBL] [Abstract][Full Text] [Related]
30. The immunogenicity of Alum+CpG adjuvant SARS-CoV-2 inactivated vaccine in mice.
Yang J; Li B; Yang D; Wu J; Yang A; Wang W; Lin F; Wan X; Li Y; Chen Z; Lv S; Pang D; Liao W; Meng S; Lu J; Guo J; Wang Z; Shen S
Vaccine; 2023 Sep; 41(41):6064-6071. PubMed ID: 37640568
[TBL] [Abstract][Full Text] [Related]
31. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine.
Li CJ; Jiang CL; Chao TL; Lin SY; Tsai YM; Chao CS; Su YT; Chen CJ; Chang SY; Lin FJ; Chang SC
Appl Microbiol Biotechnol; 2023 May; 107(9):2983-2995. PubMed ID: 36988669
[TBL] [Abstract][Full Text] [Related]
32. Preparation and pre-clinical evaluation of flagellin-adjuvanted NOM vaccine candidate formulated with Spike protein against SARS-CoV-2 in mouse model.
Farshidi N; Ghaedi T; Hassaniazad M; Eftekhar E; Gouklani H; Farshidi H; Asadi Karam MR; Shahbazi B; Kalani M; Ahmadi K
Microb Pathog; 2022 Oct; 171():105736. PubMed ID: 36030048
[TBL] [Abstract][Full Text] [Related]
33. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.
Takasuka N; Fujii H; Takahashi Y; Kasai M; Morikawa S; Itamura S; Ishii K; Sakaguchi M; Ohnishi K; Ohshima M; Hashimoto S; Odagiri T; Tashiro M; Yoshikura H; Takemori T; Tsunetsugu-Yokota Y
Int Immunol; 2004 Oct; 16(10):1423-30. PubMed ID: 15314040
[TBL] [Abstract][Full Text] [Related]
34. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
35. Two formulations of coronavirus disease-19 recombinant subunit vaccine candidate made up of S1 fragment protein P1, S2 fragment protein P2, and nucleocapsid protein elicit strong immunogenicity in mice.
Özcengiz E; Keser D; Özcengiz G; Çelik G; Özkul A; İnçeh FN
Immun Inflamm Dis; 2022 Dec; 10(12):e748. PubMed ID: 36444622
[TBL] [Abstract][Full Text] [Related]
36. A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.
Steinbuck MP; Seenappa LM; Jakubowski A; McNeil LK; Haqq CM; DeMuth PC
Sci Adv; 2021 Feb; 7(6):. PubMed ID: 33547083
[TBL] [Abstract][Full Text] [Related]
37. Montanide ISA-720 and Naloxone in HBsAg Vaccine Formulation: Cytokine Profiling and Monitoring of Long-Lasting Humoral Immune Responses.
Mirzaee M; Haghighat S; Golkaran B; Asgarhalvaei F; Mirzaee R; Taghizadeh M; Savoji MA; Esfandiari B; Mahdavi M
Biomed Environ Sci; 2022 Sep; 35(9):792-803. PubMed ID: 36189994
[TBL] [Abstract][Full Text] [Related]
38. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
39. Nano-multilamellar lipid vesicles promote the induction of SARS-CoV-2 immune responses by a protein-based vaccine formulation.
Rodrigues-Jesus MJ; Teixeira de Pinho Favaro M; Venceslau-Carvalho AA; de Castro-Amarante MF; da Silva Almeida B; de Oliveira Silva M; Andreata-Santos R; Gomes Barbosa C; Brito SCM; Freitas-Junior LH; Boscardin SB; de Souza Ferreira LC
Nanomedicine; 2022 Sep; 45():102595. PubMed ID: 36031045
[TBL] [Abstract][Full Text] [Related]
40. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
